Cargando…

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the development of anticancer immunotherapy agents has thrived. The success of many immune-checkpoint inhibitors has drastically changed the landscape of cancer treatment. For some types of cancer, monotherapy for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yifan, Deng, Weiye, Li, Nan, Neri, Shinya, Sharma, Amrish, Jiang, Wen, Lin, Steven H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844965/ https://www.ncbi.nlm.nih.gov/pubmed/29556198 http://dx.doi.org/10.3389/fphar.2018.00185

Ejemplares similares

Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions
por: David, Steven, et al.
Publicado: (2022)

The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review
por: Kong, Fanming, et al.
Publicado: (2021)

Current Evidence and Future Directions of Berberine Intervention in Depression
por: Zhu, Wen-Qian, et al.
Publicado: (2022)

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions
por: Yan, Zhi-Ling, et al.
Publicado: (2022)

Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives
por: Zulfiqar, Bilal, et al.
Publicado: (2022)

A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges
por: Chen, Ying, et al.
Publicado: (2023)

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics
por: Chua, E. W., et al.
Publicado: (2012)

Adenosine Receptor-Mediated Cardioprotection—Current Limitations and Future Directions
por: Lasley, Robert D.
Publicado: (2018)

Cellular Senescence and Senotherapies in the Kidney: Current Evidence and Future Directions
por: Docherty, Marie Helena, et al.
Publicado: (2020)

The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions
por: Shams, Shahin, et al.
Publicado: (2021)

Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions
por: Spisni, Enzo, et al.
Publicado: (2022)

Radiotherapy–immunotherapy combinations – perspectives and challenges
por: Mondini, Michele, et al.
Publicado: (2020)

Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
por: De Ponti, Fabrizio
Publicado: (2013)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
por: Yu, Chao-Chao, et al.
Publicado: (2022)

Combining radiotherapy with immunotherapy: the past, the present and the future
por: Van Limbergen, Evert J, et al.
Publicado: (2017)

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
por: Sarkar, Chandan, et al.
Publicado: (2020)

Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization
por: Rajeev-Kumar, Greeshma, et al.
Publicado: (2022)

Current status and future directions of cancer immunotherapy
por: Zhang, Hongming, et al.
Publicado: (2018)

Immunotherapy in HIV infection; current and future challenges
por: Lévy, Yves
Publicado: (2010)

Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions
por: Cella, David, et al.
Publicado: (2022)

Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges
por: van Aken, Evert S.M., et al.
Publicado: (2022)

Current clinical trials testing the combination of immunotherapy with radiotherapy
por: Kang, Josephine, et al.
Publicado: (2016)

The Hyperactivity–Impulsivity–Irritiability–Disinhibition–Aggression–Agitation Domain in Alzheimer’s Disease: Current Management and Future Directions
por: Keszycki, Rachel M., et al.
Publicado: (2019)

Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges
por: Kardas, Przemysław, et al.
Publicado: (2022)

Editorial: Translation and implementation of pharmacogenomic testing in daily clinical practice: Considering current challenges and future needs
por: Miltyk, Wojciech, et al.
Publicado: (2022)

Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
por: Qian, Jack M., et al.
Publicado: (2021)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
por: Li, Huixia, et al.
Publicado: (2023)

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges
por: Zhang, Xi, et al.
Publicado: (2022)

An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
por: Ye, Qingmei, et al.
Publicado: (2023)

Combining immunotherapy and radiotherapy in lung cancer: a promising future?
por: Zhou, Jieling, et al.
Publicado: (2020)

Immunotherapy in Lung Cancer: Current Landscape and Future Directions
por: Mamdani, Hirva, et al.
Publicado: (2022)

Current Status and Future Directions of Bacteria-Based Immunotherapy
por: Tang, Quan, et al.
Publicado: (2022)

Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
por: Yang, Minfeng, et al.
Publicado: (2020)

Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges
por: Jin, Jing, et al.
Publicado: (2020)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities
por: Li, Wen-Hao, et al.
Publicado: (2023)

Current State and Future Directions of Intranasal Delivery Route for Central Nervous System Disorders: A Scientometric and Visualization Analysis
por: Wu, Haiyang, et al.
Publicado: (2021)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

Editorial: Food/Diet Supplements From Natural Sources: Current Status and Future Challenges From a Pharmacological Perspective
por: Tomczyk, Michał, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cof48d6he3mt4hbcqbvuv12sh6